Predictive Biosciences

High-Level Overview

Predictive Biosciences is a biotechnology company founded in 2006, specializing in molecular diagnostic tests for cancer diagnosis and monitoring, particularly in urology with a focus on bladder and prostate cancer.[2][4][5] The company develops innovative assays like the CertNDx bladder cancer test, which combines DNA and protein biomarkers via its proprietary Multi-Analyte Diagnostic Readout (MADR™) technology to enable non-invasive cancer detection with high accuracy.[4] It serves physicians and patients by addressing unmet needs in cancer management through CLIA-certified laboratory services, generating $5.7 million in revenue (2024) with $46.8 million in total funding and 11 employees based in Lexington, Massachusetts.[2][4]

The company solves critical problems in oncology diagnostics by providing tools for earlier, more precise detection and monitoring, reducing reliance on invasive procedures like biopsies.[2][4] Growth momentum includes a $25 million Series C financing in an undisclosed year (pre-2025), led by ProQuest Investments with participation from Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, and New Enterprise Associates, funding multi-center clinical trials and commercial launch of its bladder cancer assay.[4]

Origin Story

Predictive Biosciences was founded in 2006 in Lexington, Massachusetts, as a fully-integrated developer of molecular diagnostic cancer assays with a urology focus.[2][4] Key early leadership included Peter Klemm, Ph.D., who served as president and CEO during its Series C funding, emphasizing the company's vision for innovative cancer diagnostics.[4] The idea emerged from leveraging patented biomarkers and clinical approaches to build assays for cancer management, starting with bladder and prostate cancers, amid growing demand for non-invasive diagnostics.[4][5]

Pivotal moments include securing $46.8 million in total funding, culminating in the $25 million Series C round to advance clinical trials and commercialization of the CertNDx assay through its CLIA labs.[2][4] This support from prominent investors like ProQuest (with Jay Moorin joining the board) marked a shift toward commercial-stage expansion.[4]

Core Differentiators

• Novel Multi-Analyte Technology: CertNDx uses MADR™ to integrate DNA and protein biomarkers in a single non-invasive assay, offering high certainty in detecting bladder cancer presence or absence—superior to traditional methods.[4]
• Urology-Focused Portfolio: Specializes in bladder and prostate cancer assays, combined with anatomic pathology lab services, meeting physician needs for precise, subspecialty diagnostics.[2][4][5]
• Commercial Infrastructure: Operates CLIA-certified labs for rapid development-to-commercialization, supported by $46.8 million funding and partnerships enabling multi-center trials.[2][4]
• Track Record in Biotech: $5.7 million revenue (2024) with a lean team of 11, positioning it as an agile player against competitors like Biodesix and Asuragen in health diagnostics.[2]

Role in the Broader Tech Landscape

Predictive Biosciences rides the wave of precision oncology and liquid biopsy trends, where molecular diagnostics enable earlier cancer intervention without invasive procedures.[2][4][5] Timing aligns with rising demand for non-invasive urologic cancer tools, fueled by aging populations and advances in biomarker tech, positioning it favorably in a market projected for growth in personalized medicine.[4]

It influences the ecosystem by pioneering multi-analyte assays that enhance physician decision-making, potentially reducing healthcare costs and improving outcomes in bladder/prostate cancer management—high-incidence areas with diagnostic gaps.[2][4][5] Backed by top VCs, it exemplifies how biotech startups scale lab services amid favorable forces like regulatory support for companion diagnostics.

Quick Take & Future Outlook

Predictive Biosciences is poised for expansion post-Series C, with CertNDx commercialization driving revenue beyond $5.7 million through broader urology adoption and potential pipeline growth into other cancers.[2][4] Trends like AI-enhanced biomarkers and expanded liquid biopsies will shape its path, amplifying sensitivity and market reach. Its influence may evolve from niche urology innovator to broader oncology diagnostics leader, especially if it leverages funding for new assays—tying back to its core mission of transforming cancer management with precise, accessible tools.[4][5]